Atezolizumab plus Bevacizumab Treatment Worsens Liver Reserve in Patients with Nafld/Nash-Associated Liver Cancer More than in Those with Non-nafld/Non-Nash-Associated Liver Cancer
How to cite: Sugimoto, R.; Motomura, K.; Satoh, T.; Tanaka, Y.; Yamashita, S.; Higuchi, N.; Koyanagi, T.; Nakamura, T.; Tanaka, M.; Azuma, Y.; Goya, T.; Kuwano, A.; Ooho, A.; Ooe, M.; Mutsuki, T.; Kuniyoshi, M.; Kurosaka, K.; Morita, Y.; Tada, S.; Aratake, Y.; Yoshimoto, T.; Senju, T.; Kurashige, T.; Harada, S.; Ueda, A.; Miyazaki, M.; Nakamuta, M.; Kohjima, M. Atezolizumab plus Bevacizumab Treatment Worsens Liver Reserve in Patients with Nafld/Nash-Associated Liver Cancer More than in Those with Non-nafld/Non-Nash-Associated Liver Cancer. Preprints 2023, 2023101682. https://doi.org/10.20944/preprints202310.1682.v1 Sugimoto, R.; Motomura, K.; Satoh, T.; Tanaka, Y.; Yamashita, S.; Higuchi, N.; Koyanagi, T.; Nakamura, T.; Tanaka, M.; Azuma, Y.; Goya, T.; Kuwano, A.; Ooho, A.; Ooe, M.; Mutsuki, T.; Kuniyoshi, M.; Kurosaka, K.; Morita, Y.; Tada, S.; Aratake, Y.; Yoshimoto, T.; Senju, T.; Kurashige, T.; Harada, S.; Ueda, A.; Miyazaki, M.; Nakamuta, M.; Kohjima, M. Atezolizumab plus Bevacizumab Treatment Worsens Liver Reserve in Patients with Nafld/Nash-Associated Liver Cancer More than in Those with Non-nafld/Non-Nash-Associated Liver Cancer. Preprints 2023, 2023101682. https://doi.org/10.20944/preprints202310.1682.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)